NCT02397083 - Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

September 23, 2015

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Atypical Endometrial HyperplasiaFIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Interventions

DRUG

Everolimus

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DEVICE

Levonorgestrel-Releasing Intrauterine System

Placed in the uterus

Trial Locations (18)

11042

Northwell Health, New Hyde Park

22908

University of Virginia Cancer Center, Charlottesville

44903

OhioHealth Mansfield Hospital, Mansfield

48604

Covenant HealthCare Mackinaw, Saginaw

73104

University of Oklahoma Health Sciences Center, Oklahoma City

77024

Memorial Hermann Memorial City Medical Center, Houston

77030

M D Anderson Cancer Center, Houston

77054

The Woman's Hospital of Texas, Houston

77079

MD Anderson West Houston, Houston

77384

MD Anderson in The Woodlands, Conroe

77478

MD Anderson in Sugar Land, Sugar Land

77573

MD Anderson League City, League City

80539

McKee Medical Center, Loveland

80631

North Colorado Medical Center, Greeley

96813

Queen's Medical Center, Honolulu

08103

Cooper Hospital University Medical Center, Camden

08043

MD Anderson Cancer Center at Cooper-Voorhees, Voorhees Township

77026-1967

Lyndon Baines Johnson General Hospital, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER